Ticker Details
Xencor, Inc. Xencor Inc is engaged in the field of biotechnology. The United States-based firm develops drugs to combat severe diseases such as allergies and cancers.
IPO Date:	December 3, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.07B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.58 | 2.53%
Avg Daily Range (30 D):	$0.78 | 3.97%
Avg Daily Range (90 D):	$0.54 | 3.45%

Institutional Daily Volume
Avg Daily Volume:	.3M
Avg Daily Volume (30 D):	.9M
Avg Daily Volume (90 D):	.71M

Trade Size
Avg Trade Size (Sh.):	67
Avg Trade Size (Sh.) (30 D):	64
Avg Trade Size (Sh.) (90 D):	53

Institutional Trades
Total Institutional Trades:	3,406
Avg Institutional Trade:	$2.01M
Avg Institutional Trade (30 D):	$2.75M
Avg Institutional Trade (90 D):	$2.49M
Avg Institutional Trade Volume:	.09M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.27M
Avg Closing Trade (30 D):	$3.76M
Avg Closing Trade (90 D):	$2.84M
Avg Closing Volume:	96.05K

News

Feb 18, 2026 @ 4:00 PM CTLA-4 Inhibitors Competitive Landscape Research R... Source: Researchandmarkets.Com

Jan 14, 2026 @ 8:30 AM [Latest] Global T-Cell Engagers Market Size/Share ... Source: Custom Market Insights

Aug 6, 2025 @ 8:13 PM Xencor (XNCR) Q2 Revenue Jumps 82% Source: Not Specified

Jul 16, 2025 @ 4:30 AM [Latest] Global Ultomiris Drug Market Size/Share W... Source: Custom Market Insights

Sep 12, 2024 @ 5:09 PM Xencor Surges 10.5%: Is This an Indication of Furt... Source: Zacks

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-2.17	$-.29	$-1.71
Diluted EPS	$-2.17	$-.29	$-1.71
Revenue	$104.97M	$51.22M	$4.52M
Gross Profit
Net Income / Loss	$-163.33M	$-21.73M	$-128.92M
Operating Income / Loss	$-216.08M	$-37.07M	$-77.86M
Cost of Revenue
Net Cash Flow	$.13M	$30.49M	$-40M
PE Ratio